Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-29
2010-10-19
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S329000, C424S146100
Reexamination Certificate
active
07816325
ABSTRACT:
The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.
REFERENCES:
patent: 6376549 (2002-04-01), Fine et al.
patent: WO-01/97808 (2001-12-01), None
Hinke, 2002, Biochemical and Biophysical research Communications, 291, 1302-1308.
Wakimasu, 1978, Chem. Pharm. Bull., 26, 1522-1526.
Kuhn-Wache, 2001, 2nd General meeting of the International Proteolysis Society (IPS), Abstract P. 17, 2 pages.
Bär Joachim
Brandt Wolfgang
Demuth Hans-Ulrich
Heiser Ulrich
Hoffmann Torsten
Gudibande Satyanarayana R
Kosar Andrew D
OSI Pharmaceuticals Inc.
OSI Pharmaceuticals, Inc.
Rafa Michael J.
LandOfFree
Secondary binding site of dipeptidyl peptidase IV (DP IV) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Secondary binding site of dipeptidyl peptidase IV (DP IV), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Secondary binding site of dipeptidyl peptidase IV (DP IV) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4231599